microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells

Cellular and Molecular Neurobiology

Volumn 34, Issue 5, 2014, Pages 679-692

  Tezcan, Gulcin ^a   Tunca, Berrin ^a   Bekar, Ahmet ^a   Preusser, Matthias ^b   Berghoff, Anna Sophie ^b   Egeli, Unal ^a   Cecener, Gulsah ^a   Ricken, Gerda ^c   Budak, Ferah ^a   Taskapılıoglu, Mevlut Ozgur ^a   Kocaeli, Hasan ^a   Tolunay, Sahsine ^a  

^a ULUDAG UNIVERSITY   (Turkey)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cancer stem cell; Glioblastoma; microRNA; Temozolomide; Therapy

Indexed keywords

BIOLOGICAL MARKER; GENOMIC DNA; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; MICRORNA 10A; MICRORNA 10B; MICRORNA 137; MICRORNA 145; MICRORNA 153; MICRORNA 181B; MICRORNA 455 3P; MICRORNA 7D; MICRORNA 9; SMAD2 PROTEIN; TEMOZOLOMIDE; TUMOR MARKER; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DEREGULATION; DNA METHYLATION; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAGNETIC SEPARATION; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BRAIN NEOPLASMS; COHORT ANALYSIS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MORTALITY; PHYSIOLOGY; TREATMENT OUTCOME; TRENDS; TUMOR CELL CULTURE;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COHORT STUDIES; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASTIC STEM CELLS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 84904115160     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-014-0050-0     Document Type: Article

References (76)

1. Altaner C (2008) Glioblastoma and stem cells. Neoplasma 55:369-374
2. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215-233
3. Bier A, Giladi N, Kronfeld N et al (2013) MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget 4(5):665-676
4. Bisso A, Faleschini M, Zampa F et al (2013) Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 12(11):1679-1687
5. Brescia P, Ortensi B, Fornasari L et al (2013) CD133 is essential for glioblastoma stem cell maintenance. Stem Cells 31(5):857-869
6. Bruna A, Darken RS, Rojo F et al (2007) High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11(2):147-160 (Pubitemid 46209848)
7. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866 (Pubitemid 44629897)
8. Calin GA, Pekarsky Y, Croce CM (2007) The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20(3):425-437 (Pubitemid 47260321)
9. Cecener G, Tunca B, Egeli U et al (2012) The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma. Cell Mol Neurobiol 32(2):237-244
10. Cheng WY, Kandel JJ, Yamashiro DJ et al (2012) A multi-cancer mesenchymal transition gene expression signature is associated with prolonged time to recurrence in glioblastoma. PLoS One 7(4):e34705
11. Dirks PB (2005) Brain tumor stem cells. Biol Blood Marrow Transpl 11(2 Suppl 2):12-13
12. Esquela-Kerscher A, Slack FJ (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6:259-269
13. Everhard S, Tost J, El Abdalaoui H et al (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol 11(4):348-356
14. Galli R, Binda E, Orfanelli U (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64:7011-7021 (Pubitemid 39331011)
15. Guessous F, Alvarado-Velez M, Marcinkiewicz L et al (2013) Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol 112(2):153-163
16. Haapa-Paananen S, Chen P, Hellström K et al (2013) Functional profiling of precursor MicroRNAs identifies MicroRNAs essential for glioma proliferation. PLoS One 8(4):e60930
17. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997-1003 (Pubitemid 40349502)
18. Hemmati HD, Nakano I, Lazareff JA et al (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100:15178-15183 (Pubitemid 37518036)
19. Hirata H, Hinoda Y, Ueno K et al (2012) MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis 33(1):41-48
20. Hummel R, Hussey DJ, Haier J (2010) MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 46(2):298-311
21. Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11(4):341-347
22. Ignatova TN, Kukekov VG, Laywell ED et al (2002) Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39:193-206
23. Jeon HM, Sohn YW, Oh SY et al (2011) ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res 71(9):3410-3421
24. Jones DT, Kocialkowski S, Liu LETAL (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68(21):8673-8677
25. Kloth JN, Kenter GG, Spijker HS et al (2008) Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival. Mod Pathol 21(7):866-875 (Pubitemid 351896661)
26. Koo S, Martin GS, Schulz KJ et al (2012) Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines. BMC Cancer 10(12):143
27. Kreth S, Limbeck E, Hinske LC et al (2013) In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing. Acta Neuropathol 125(5):671-681
28. Lathia JD, Gallagher J, Myers JT et al (2011) Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One 6(9):e24807
29. Lee ST, Chu K, Oh HJ et al (2011) Let-7 microRNA inhibits the proliferation of human glioblastoma cells. J Neurooncol 102:19-24
30. Lee HK, Bier A, Cazacu S et al (2013) MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS One 8(2):e54652
31. Leibetseder A, Ackerl M, Flechl B et al (2013) Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). Neuro Oncol 15(1):112-121
32. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicated that thousands of human genes are microRNA targets. Cell 120:15-20 (Pubitemid 40094598)
33. Li Y, VandenBoom TG 2nd, Kong D et al (2009) Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69(16):6704-6712
34. Li P, Lu X, Wang Y et al (2010) MiR-181b suppresses proliferation of and reduces chemoresistance to temozolomide in U87 glioma stem cells. J Biomed Res 24(6):436-443
35. Liu G, Yuan X, Zeng Z et al (2006) Analysis of gene expression and chemoresistance of CD133+cancer stem cells in glioblastoma. Mol Cancer 5:67
36. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Δ Δ C(T)) method. Methods 25:402-408 (Pubitemid 34164012)
37. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109 (Pubitemid 47103521)
38. M-Chang CJ, Hsu CC, Chang CH et al (2011) Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemo-resistant property in oral cancer. Oncol Rep 26(4):1003-1010
39. Melguizo C, Prados J, González B et al (2012) MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J Transl Med 17(10):250
40. Munoz JL, Bliss SA, Greco SJ et al (2013) Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids 1(2):e126
41. Nakano I, Kornblum HI (2006) Brain tumor stem cells. Pediatr Res 59(4 Pt 2):54R-58R (Pubitemid 43740036)
42. Nishida N, Yamashita S, Mimori K et al (2012) MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol 19(9):3065-3071
43. Nobusawa S, Watanabe T, Kleihues P et al (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15(19):6002-6007
44. Okamoto OK, Oba-Shinjo SM, Lopes L et al (2007) Expression of HOXC9 and E2F2 are up-regulated in CD 133+ cells isolated from human astrocytomas and associated with transformation of human astrocytes. Biochim Biophys Acta 1769:437-442 (Pubitemid 47081204)
45. Oliver TG, Wechsler-Reya RJ (2004) Getting at the root and stem of brain tumors. Neuron 42:885-888 (Pubitemid 38798227)
46. Persano L, Pistollato F, Rampazzo E et al (2012) BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression. Cell Death Dis 18(3):e412
47. Pistollato F, Abbadi S, Rampazzo E et al (2010) Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 28:851-862
48. Ramakrishnan V, Kushwaha D, Koay DC et al (2011) Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas. Cancer Biomark 10(3-4):185-193
49. Rani SB, Rathod SS, Karthik S et al (2013) MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells. Neuro Oncol 15(10):1302-1316
50. Revelos K, Petraki C, Gregorakis A et al (2005) Immunohistochemical expression of Bcl2 is an independent predictor of time-tobiochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res 25(4):3123-3133
51. Reya T, Morrison SJ, Clarke MF et al (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105-111 (Pubitemid 33041634)
52. Rorke LB (1997) Pathologic diagnosis as the gold standard. Cancer 79:665-667
53. Sanchez-Martin M (2008) Brain tumour stem cells: implications for cancer therapy and regenerative medicine. Curr Stem Cell Res Ther 3:197-207
54. Sato A, Sunayama J, Matsuda K et al (2011) MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Stem Cells 29(12):1942-1951
55. Shi L, Cheng Z, Zhang J et al (2008) hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res 1236:185-193
56. Shi M, Du L, Liu D et al (2012) Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. J Pathol 228(2):148-157
57. Singh SK, Clarke ID, Terasaki M et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821-5828 (Pubitemid 37187480)
58. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459-466
59. Swingler TE, Wheeler G, Carmont V et al (2012) The expression and function of microRNAs in chondrogenesis and osteoarthritis. Arthritis Rheum 64(6):1909-1919
60. Sze CI, Su WP, Chiang MF et al (2013) Assessing current therapeutic approaches to decode potential resistance mechanisms in glioblastomas. Front Oncol 19(3):59
61. Takwi AA, Wang YM, Wu J et al (2013) miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells. Oncogene. doi:10.1038/onc.2013.330
62. Tunca B, Tezcan G, Cecener G et al (2012) Olea europaea leaf extract alters microRNA expression in human glioblastoma cells. J Cancer Res Clin Oncol 138(11):1831-1844
63. Ujifuku K, Mitsutake N, Takakura S et al (2010) miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 296(2):241-248
64. Valledor AF, Arpa L, Sanchez-Tillo E et al (2008) IFN-{gamma}- mediated inhibition of MAPK phosphatase expression results in prolonged MAPK activity in response to M-CSF and inhibition of proliferation. Blood 112(8):3274-3282
65. Visone R, Veronese A, Rassenti LZ et al (2011) miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 118(11):3072-3079
66. Wang B, Hsu SH, Majumder S et al (2010) TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 29(12):1787-1797
67. Wang B, Li W, Guo K et al (2012) miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun 421(1):4-8
68. Wang J, Sai K, Chen FR et al (2013) miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol 72(1):147-158
69. Weller M, Pfister SM, Wick W et al (2013) Molecular neurooncology in clinical practice: a new horizon. Lancet Oncol 14(9):e370-e379
70. Wu W, Pew T, Zou M et al (2005) Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 280(6):4117-4124 (Pubitemid 40288576)
71. Zhang L, Sato E, Amagasaki K et al (2006) Participation of an abnormality in the transforming growth factor-beta signaling pathway in resistance of malignant glioma cells to growth inhibition induced by that factor. J Neurosurg 105:119-128 (Pubitemid 43979106)
72. Zhang L, Pickard K, Jenei V et al (2013) miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res 73(21):6435-6447
73. Zhao S, Deng Y, Liu Y et al (2013) MicroRNA-153 is tumor suppressive in glioblastoma stem cells. Mol Biol Rep 40(4):2789-2798
74. Zhu W, Shan X, Wang T et al (2010) miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 127(11):2520-2529
75. Zhu DX, Zhu W, Fang C et al (2012) miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis 33(7):1294-1301
76. Zhu X, Li Y, Shen H et al (2013) miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochim Biophys Sin (Shanghai) 45(2):80-86